| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medulloblastoma | 16 | 2021 | 541 | 4.430 |
Why?
|
| Cerebellar Neoplasms | 11 | 2021 | 434 | 3.530 |
Why?
|
| Repressor Proteins | 11 | 2022 | 1663 | 2.120 |
Why?
|
| Killer Cells, Natural | 3 | 2020 | 907 | 1.050 |
Why?
|
| Brain Neoplasms | 8 | 2022 | 4838 | 0.880 |
Why?
|
| Schiff Bases | 1 | 2021 | 3 | 0.810 |
Why?
|
| Hedgehog Proteins | 3 | 2021 | 423 | 0.800 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2021 | 36 | 0.770 |
Why?
|
| DNA End-Joining Repair | 1 | 2021 | 87 | 0.750 |
Why?
|
| Radiation, Ionizing | 1 | 2021 | 189 | 0.740 |
Why?
|
| Ependymoma | 2 | 2020 | 247 | 0.730 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 218 | 0.680 |
Why?
|
| Patched-1 Receptor | 1 | 2019 | 48 | 0.670 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2021 | 362 | 0.670 |
Why?
|
| Epigenomics | 2 | 2020 | 265 | 0.660 |
Why?
|
| Enzyme Inhibitors | 4 | 2018 | 1879 | 0.650 |
Why?
|
| Fluorine Radioisotopes | 1 | 2019 | 132 | 0.640 |
Why?
|
| Histone Demethylases | 1 | 2018 | 144 | 0.590 |
Why?
|
| Drug Monitoring | 1 | 2019 | 337 | 0.570 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2019 | 286 | 0.550 |
Why?
|
| Endopeptidases | 2 | 2017 | 220 | 0.520 |
Why?
|
| Valproic Acid | 4 | 2010 | 263 | 0.500 |
Why?
|
| DNA Replication | 5 | 2013 | 746 | 0.490 |
Why?
|
| Chromatin | 2 | 2022 | 950 | 0.490 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 1545 | 0.470 |
Why?
|
| Cell Proliferation | 8 | 2021 | 7241 | 0.470 |
Why?
|
| Mice, Inbred NOD | 3 | 2021 | 904 | 0.440 |
Why?
|
| Myoblasts | 2 | 2010 | 72 | 0.430 |
Why?
|
| Cell Line, Tumor | 17 | 2022 | 14561 | 0.420 |
Why?
|
| Cell Movement | 2 | 2019 | 2462 | 0.400 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2011 | 43 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 2062 | 0.390 |
Why?
|
| Mice, SCID | 3 | 2021 | 1865 | 0.390 |
Why?
|
| DNA Topoisomerases, Type II | 2 | 2010 | 117 | 0.380 |
Why?
|
| Papillomaviridae | 4 | 1999 | 612 | 0.360 |
Why?
|
| DNA, Viral | 3 | 1999 | 675 | 0.360 |
Why?
|
| Osteosarcoma | 3 | 2023 | 920 | 0.350 |
Why?
|
| Cell Differentiation | 6 | 2012 | 4043 | 0.340 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 60 | 0.330 |
Why?
|
| Pyrimidines | 1 | 2021 | 3538 | 0.330 |
Why?
|
| Tretinoin | 1 | 2011 | 622 | 0.320 |
Why?
|
| Neuroblastoma | 2 | 2011 | 683 | 0.320 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 205 | 0.320 |
Why?
|
| Cell Cycle Proteins | 3 | 2022 | 2053 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2022 | 8882 | 0.290 |
Why?
|
| Cerebellum | 1 | 2010 | 445 | 0.290 |
Why?
|
| Oncogenes | 2 | 2022 | 669 | 0.290 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2017 | 590 | 0.290 |
Why?
|
| Thiadiazoles | 3 | 2016 | 47 | 0.280 |
Why?
|
| Apoptosis | 7 | 2019 | 7601 | 0.280 |
Why?
|
| Histone Deacetylase Inhibitors | 5 | 2012 | 612 | 0.270 |
Why?
|
| Animals | 22 | 2022 | 59489 | 0.270 |
Why?
|
| Mice | 17 | 2022 | 34393 | 0.270 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2007 | 521 | 0.270 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2021 | 3818 | 0.260 |
Why?
|
| Histones | 5 | 2020 | 1462 | 0.250 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2018 | 454 | 0.240 |
Why?
|
| Bone Neoplasms | 3 | 2023 | 2559 | 0.240 |
Why?
|
| Humans | 41 | 2023 | 262248 | 0.240 |
Why?
|
| Neurons | 3 | 2010 | 2290 | 0.230 |
Why?
|
| Virus Replication | 2 | 1999 | 706 | 0.230 |
Why?
|
| Oncogene Proteins, Viral | 3 | 1999 | 132 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 7717 | 0.220 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 7218 | 0.220 |
Why?
|
| Glioblastoma | 4 | 2010 | 1799 | 0.220 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 4126 | 0.210 |
Why?
|
| Etoposide | 3 | 2010 | 873 | 0.200 |
Why?
|
| Cells, Cultured | 4 | 2021 | 5598 | 0.200 |
Why?
|
| Child | 10 | 2022 | 29067 | 0.200 |
Why?
|
| DNA Ligase ATP | 1 | 2021 | 51 | 0.200 |
Why?
|
| DNA-Binding Proteins | 4 | 2010 | 4787 | 0.200 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2021 | 319 | 0.200 |
Why?
|
| Glioma | 3 | 2022 | 1940 | 0.200 |
Why?
|
| Schizosaccharomyces | 1 | 2001 | 117 | 0.190 |
Why?
|
| DNA, Fungal | 1 | 2001 | 128 | 0.190 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2010 | 1063 | 0.190 |
Why?
|
| Infusions, Intraventricular | 1 | 2020 | 29 | 0.190 |
Why?
|
| Fungal Proteins | 1 | 2001 | 254 | 0.190 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2021 | 166 | 0.180 |
Why?
|
| RNA Splicing | 1 | 2022 | 369 | 0.180 |
Why?
|
| Brain Stem Neoplasms | 1 | 2020 | 100 | 0.170 |
Why?
|
| Sarcoma, Ewing | 1 | 2023 | 406 | 0.170 |
Why?
|
| Ubiquitin | 2 | 2017 | 344 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 4 | 2019 | 5378 | 0.150 |
Why?
|
| Histocompatibility Antigens | 1 | 2017 | 74 | 0.150 |
Why?
|
| Interleukin-2 | 1 | 2020 | 842 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2016 | 856 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 621 | 0.150 |
Why?
|
| Benzothiazoles | 1 | 2017 | 94 | 0.140 |
Why?
|
| Benzene Derivatives | 1 | 2016 | 23 | 0.140 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 76 | 0.140 |
Why?
|
| Tubulin Modulators | 1 | 2016 | 65 | 0.140 |
Why?
|
| Homeodomain Proteins | 2 | 2013 | 1139 | 0.140 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 1077 | 0.140 |
Why?
|
| Proteasome Inhibitors | 1 | 2017 | 230 | 0.140 |
Why?
|
| Stathmin | 2 | 2019 | 30 | 0.140 |
Why?
|
| Antineoplastic Agents | 6 | 2021 | 14288 | 0.140 |
Why?
|
| Fluorine-19 Magnetic Resonance Imaging | 1 | 2016 | 6 | 0.140 |
Why?
|
| Stilbenes | 1 | 2016 | 88 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2023 | 881 | 0.140 |
Why?
|
| Epigenesis, Genetic | 2 | 2020 | 1397 | 0.130 |
Why?
|
| Models, Biological | 3 | 2012 | 3242 | 0.130 |
Why?
|
| Tubulin | 2 | 2016 | 168 | 0.130 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2015 | 81 | 0.120 |
Why?
|
| Rhabdoid Tumor | 1 | 2015 | 108 | 0.120 |
Why?
|
| Cytotoxins | 1 | 2014 | 65 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2018 | 1064 | 0.120 |
Why?
|
| Mitosis | 1 | 2016 | 612 | 0.120 |
Why?
|
| Benzamides | 3 | 2009 | 1834 | 0.120 |
Why?
|
| Methotrexate | 2 | 2015 | 1002 | 0.120 |
Why?
|
| Cell Survival | 2 | 2018 | 3042 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 797 | 0.120 |
Why?
|
| Chromosome Fragility | 1 | 2013 | 32 | 0.120 |
Why?
|
| G-Quadruplexes | 1 | 2013 | 17 | 0.120 |
Why?
|
| Transcription, Genetic | 2 | 2012 | 3127 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 2 | 2016 | 1077 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 3632 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 15874 | 0.110 |
Why?
|
| Sarcoma | 1 | 2023 | 1725 | 0.110 |
Why?
|
| Pyridines | 3 | 2009 | 1243 | 0.110 |
Why?
|
| Mice, Knockout | 2 | 2019 | 5672 | 0.100 |
Why?
|
| Viral Proteins | 1 | 1994 | 437 | 0.100 |
Why?
|
| DNA Methylation | 2 | 2020 | 2671 | 0.100 |
Why?
|
| Protein Stability | 1 | 2012 | 371 | 0.100 |
Why?
|
| Contactin 2 | 1 | 2010 | 8 | 0.100 |
Why?
|
| Clinical Decision-Making | 1 | 2015 | 526 | 0.100 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2012 | 606 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 283 | 0.100 |
Why?
|
| Indoles | 1 | 2016 | 1011 | 0.090 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 154 | 0.090 |
Why?
|
| Proteolysis | 1 | 2012 | 368 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 2860 | 0.090 |
Why?
|
| Base Sequence | 4 | 2022 | 4886 | 0.090 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 305 | 0.090 |
Why?
|
| Histone Deacetylases | 1 | 2012 | 364 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 1493 | 0.090 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2014 | 566 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 5183 | 0.090 |
Why?
|
| Neurogenesis | 1 | 2012 | 237 | 0.090 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 444 | 0.090 |
Why?
|
| Binding Sites | 3 | 2022 | 2170 | 0.090 |
Why?
|
| Adolescent | 5 | 2020 | 31239 | 0.090 |
Why?
|
| Transcription Factors | 4 | 2022 | 5253 | 0.090 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2009 | 25 | 0.080 |
Why?
|
| Choroid Plexus | 1 | 2008 | 32 | 0.080 |
Why?
|
| Caspase 8 | 1 | 2009 | 145 | 0.080 |
Why?
|
| Imidazoles | 1 | 2014 | 1003 | 0.080 |
Why?
|
| HeLa Cells | 3 | 2017 | 1642 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 446 | 0.080 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2010 | 289 | 0.080 |
Why?
|
| Calcium-Binding Proteins | 1 | 2010 | 549 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 6927 | 0.080 |
Why?
|
| Translocation, Genetic | 1 | 2013 | 1244 | 0.080 |
Why?
|
| Prognosis | 2 | 2018 | 21737 | 0.080 |
Why?
|
| Replication Origin | 2 | 1999 | 21 | 0.080 |
Why?
|
| Drug Synergism | 2 | 2010 | 1316 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 591 | 0.070 |
Why?
|
| Lysine | 2 | 2020 | 419 | 0.070 |
Why?
|
| Female | 9 | 2020 | 142293 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 619 | 0.070 |
Why?
|
| Plasmids | 3 | 1999 | 833 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2020 | 2955 | 0.070 |
Why?
|
| Animals, Newborn | 1 | 2010 | 1327 | 0.070 |
Why?
|
| Gene Expression | 3 | 2013 | 3563 | 0.070 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2016 | 1765 | 0.070 |
Why?
|
| Astrocytoma | 1 | 2008 | 322 | 0.070 |
Why?
|
| Male | 6 | 2020 | 123338 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2019 | 11972 | 0.060 |
Why?
|
| Infant | 2 | 2019 | 13285 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2007 | 608 | 0.060 |
Why?
|
| Child, Preschool | 5 | 2015 | 16213 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1266 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 10067 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 3755 | 0.060 |
Why?
|
| Genes, myc | 1 | 2006 | 358 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 2485 | 0.060 |
Why?
|
| Molecular Structure | 2 | 2016 | 524 | 0.060 |
Why?
|
| K562 Cells | 2 | 2016 | 339 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 2344 | 0.060 |
Why?
|
| CD27 Ligand | 1 | 2023 | 25 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 11571 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 13669 | 0.060 |
Why?
|
| Immune Evasion | 1 | 2023 | 74 | 0.060 |
Why?
|
| Molecular Sequence Data | 3 | 2013 | 6062 | 0.060 |
Why?
|
| Acetylation | 2 | 2018 | 511 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2009 | 3529 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2009 | 3022 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2019 | 4809 | 0.050 |
Why?
|
| Receptors, Notch | 2 | 2018 | 379 | 0.050 |
Why?
|
| Spliceosomes | 1 | 2022 | 75 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2001 | 328 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2022 | 86 | 0.050 |
Why?
|
| Schizosaccharomyces pombe Proteins | 1 | 2001 | 84 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2001 | 199 | 0.050 |
Why?
|
| Cell Line, Transformed | 2 | 2008 | 391 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 4945 | 0.050 |
Why?
|
| Adult | 5 | 2022 | 78179 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 406 | 0.050 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 380 | 0.050 |
Why?
|
| Genes, Neoplasm | 1 | 2022 | 327 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2023 | 652 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 7545 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2022 | 836 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2010 | 290 | 0.040 |
Why?
|
| Stem Cells | 1 | 2006 | 1206 | 0.040 |
Why?
|
| Cell Line | 3 | 2014 | 5071 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2022 | 581 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2019 | 148 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2018 | 127 | 0.040 |
Why?
|
| Exons | 1 | 2022 | 1325 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2022 | 848 | 0.040 |
Why?
|
| Sirtuin 1 | 1 | 2018 | 87 | 0.040 |
Why?
|
| ras Proteins | 1 | 2022 | 771 | 0.040 |
Why?
|
| Polymerization | 1 | 2016 | 17 | 0.040 |
Why?
|
| Cell Cycle | 2 | 2014 | 2085 | 0.040 |
Why?
|
| Biophysical Phenomena | 1 | 2016 | 113 | 0.040 |
Why?
|
| A549 Cells | 1 | 2016 | 125 | 0.040 |
Why?
|
| Thymidine | 1 | 1995 | 151 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2017 | 147 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 304 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 337 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2017 | 278 | 0.030 |
Why?
|
| Methylation | 1 | 2017 | 591 | 0.030 |
Why?
|
| Fourth Ventricle | 1 | 2015 | 51 | 0.030 |
Why?
|
| Genes, ras | 1 | 2018 | 667 | 0.030 |
Why?
|
| Bovine papillomavirus 1 | 1 | 1994 | 8 | 0.030 |
Why?
|
| Protein Domains | 1 | 2016 | 322 | 0.030 |
Why?
|
| Cell Count | 1 | 2016 | 507 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2020 | 1991 | 0.030 |
Why?
|
| Transcriptome | 1 | 2023 | 1863 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1994 | 348 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2016 | 877 | 0.030 |
Why?
|
| Neoplasms | 2 | 2017 | 15180 | 0.030 |
Why?
|
| GC Rich Sequence | 1 | 2013 | 7 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 379 | 0.030 |
Why?
|
| Chromosome Fragile Sites | 1 | 2013 | 38 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 1557 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2013 | 104 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 2013 | 106 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2013 | 136 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2016 | 745 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2019 | 2450 | 0.030 |
Why?
|
| Adenine | 1 | 1995 | 639 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 980 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 935 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 1498 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2013 | 274 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2015 | 691 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2016 | 1740 | 0.020 |
Why?
|
| Mutation | 2 | 2022 | 15167 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 694 | 0.020 |
Why?
|
| Cyclic S-Oxides | 1 | 2010 | 12 | 0.020 |
Why?
|
| Transcription Factor HES-1 | 1 | 2010 | 49 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 3983 | 0.020 |
Why?
|
| Veratrum Alkaloids | 1 | 2010 | 32 | 0.020 |
Why?
|
| U937 Cells | 1 | 2010 | 172 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2017 | 1027 | 0.020 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2010 | 108 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 511 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2020 | 9195 | 0.020 |
Why?
|
| DNA Damage | 1 | 2017 | 1947 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2008 | 54 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 507 | 0.020 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2008 | 47 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 2804 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 3879 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 1999 | 1833 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2008 | 242 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 727 | 0.020 |
Why?
|
| Mathematical Computing | 1 | 2006 | 22 | 0.020 |
Why?
|
| Carcinogenicity Tests | 1 | 2006 | 70 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 342 | 0.020 |
Why?
|
| Kidney | 1 | 1994 | 2144 | 0.020 |
Why?
|
| Doxycycline | 1 | 2006 | 180 | 0.020 |
Why?
|
| Muscle Cells | 1 | 2004 | 38 | 0.020 |
Why?
|
| Thiazoles | 1 | 2008 | 727 | 0.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 2393 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 2915 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 33028 | 0.010 |
Why?
|
| Insecta | 1 | 1999 | 76 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2006 | 4303 | 0.010 |
Why?
|
| Carcinoma | 1 | 2008 | 2582 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 21494 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 10021 | 0.010 |
Why?
|
| Models, Genetic | 1 | 1999 | 1111 | 0.010 |
Why?
|
| Transfection | 1 | 1999 | 2934 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2008 | 38011 | 0.000 |
Why?
|